Search results
Showing 91 to 105 of 105 results for chronic heart failure in adults: management
fluid overload in people with advanced heart failure in the community:- In people with advanced heart...
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
This guideline has been updated and replaced by NICE guideline CG108.
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
Video laryngoscopes to help intubation in people with difficult airways (MIB167)
NICE has developed a medtech innovation briefing (MIB) on video laryngoscopy to help intubation in people with difficult airways .
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are
Developing NICE guidelines: the manual
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
The social care guidance manual
Show all sections
- 1 Introduction
- 2 The scope
- 3 The Guidance Development Group
- 4 Developing review questions and planning the systematic review
- 5 Identifying the evidence: literature searching and evidence submission
- 6 Reviewing the evidence
- 7 Incorporating economic evaluation
- 8 Linking social care guidance to other NICE guidance
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)